Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

ARS Pharmaceuticals, Inc. Director's Dealing 2022

Nov 10, 2022

32159_dirs_2022-11-10_e8d45316-baff-4637-99a1-8a31baf3ea18.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-11-08

Reporting Person: Karas Eric (Chief Commercial Officer)

More from ARS Pharmaceuticals, Inc.

Interim / Quarterly Report 2026
May 15
Regulatory Filings 2026
May 15
Regulatory Filings 2026
May 13
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
Director's Dealing 2026
Jan 5
View all filings →